Development of novel therapeutic target in chronic thromboembolic pulmonary hypertension

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K19360
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Cardiovascular medicine
• Research Institution: Tohoku University
• Principal Investigator: Yaoita Nobuhiro 東北大学, 東北メディカル・メガバンク機構, 助教 (00735368)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 循環器・高血圧

Outline of Final Research Achievements

The clot of chronic thromboembolic pulmonary hypertension (CTEPH) patients was more resistant to fibrinolysis than that of non-PH patients or pulmonary arterial hypertension (PAH)patients. The plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI) and the activation of TAFI were increased in CTEPH patients. Moreover, SNPs of cpb2, which induced the plasma levels of TAFI, was found in CTEPH patients. The impairment of fibrinolysis in CTEPH patients was inmproved with the inhibitor of avtivated TAFI.
In the TAFI overexpression mice, pulmonary hypertension was worse than wild type mice with hypoxic exposure and organaized thrombi ws found in pulmonary artery. Moreoover, TAFI increased the proliferation of smooth muscle cells of human.
These data suggest that TAFI could be a novel biomarker and realistic therapeutic target of CTEPH.

Free Research Field

循環器内科